🔗 Share this article

Given that the United States proceeds with historic revisions to its immunization recommendations, an unexpected name appears somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots during the pandemic and has focused upon alleged deaths following Covid immunization in her brief tenure at the FDA.

Scheduled Shifts to Pediatric Immunization Program

Agency leaders had intended to announce major changes to the childhood immunization program earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US at odds with many the global community with insufficient data for public health gain. The announcement has been delayed until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood shot schedules in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

So far public appearances, she has kept her attention on immunizations – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Questions Over Expertise

Dr. Høeg has no obvious experience in pharmaceutical research, approval processes or leadership, which has been customary for past leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for running the CDER, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in industry regulation.”

Past commissioners of CBER would “understand laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led the center have had.”

This division has an immense portfolio at the agency, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office authorizes thousands of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and every single one have to be supervised,” Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major management aspect to the job, which oversees in excess of 5,000 employees. “It’s a huge leadership role, if you execute it properly,” the former official added.

Official Statement and Contentious Policies

When asked about questions about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on immunizations, a representative said that the “questions are based on inaccurate presumptions”.

“This background aligns with the functions of her position,” the official said, noting the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s new fast-track approval initiative, a contentious rapid medication authorization process that apparently troubled her predecessors. “How are these medications being picked for this voucher program? Who makes the choices?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

In general, he remarked, “the agency looks to be trending towards laxer rules of all drugs, except for shots.”

Public Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if problematic, track record, critics have noted. She authored a analysis using non-validated public submissions to assess the rate of myocarditis after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Included in her “policy goals” for the current government included revising guidelines for novel immunizations and halting “optional” immunizations, she said after the election on a audio program. At the FDA, Dr. Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete ideologue who starts off with her preconceived notions and works backwards to retrofit the science in a highly disingenuous, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other contrarians, {like|